溴隐亭和巴氯芬对吗啡诱导成瘾后戒断症状的协同抑制作用

皮下递增注射吗啡(25、50、75、100、125、150mg/kg)建立小鼠身体依赖动物模型,把6mg/kg纳络酮作用下的小鼠跳跃症状作为成瘾后戒断的行为学观测指标,检测DA受体激动剂溴隐亭和GABAB受体激动剂巴氯芬对戒断行为的影响;同时进一步研究激动二受体在戒断过程中的作用。结果表明:溴隐亭低剂量(10mg/kg)无抑制戒断症状的作用,中、高剂量(20、30mg/kg)能够明显抑制戒断症状;巴氯芬低、中剂量(0.5、1.0mg/kg)无抑制戒断症状的作用,高剂量(1.5mg/kg)则可以抑制戒断症状的作用。当无抑制作用剂量的溴隐亭(10mg/kg)和巴氯芬(1.0mg/kg)联合应用时能够明显抑制小鼠的戒断症状,说明此二受体在吗啡成瘾后戒断期间功能上具有协同作用,能够很好地抑制纳络酮诱导的成瘾小鼠跳跃症状。

Synergetic Inhibition of Bromocrptine and Baclofen on the Naloxone-induced Withdrawal Syndromes

Mice were administrated by the consecutive morphine, subcutaneous injection (25, 50, 75, 100, 125, 150 mg/kg)to establish the withdrawal model. The naloxone (6 mg/kg)-induced responses, namely jumping behavior can be observed as withdrawal behavior. Bromocriptine and baclofen were used in the protocol and their synergetic inhibition was also studied. The results suggested that the low dose of bromocriptine (10 mg/kg) can not inhibit the withdrawal syndromes , whereas the mid (20 mg/kg) and high (30 mg/kg) doses can do. The low (0.5 mg/kg) and mid (1.0 mg/kg) doses of baclofen can not decrease the withdrawal syndromes, whereas the high dose can effectively inhibit the nalxone-induced response in the mice. However the co-administration of bromocriptine (10 mg/kg) and baclofen (1.0 mg/kg) can inhibit the withdrawal response. The results showed that the two receptors synergized and effectively inhibited the naloxone-induced withdrawal syndromes.